Diazepam Binding Inhibitor (DBI) (N-Term) Peptide
DBI
Reactivity: Human
Host: Synthetic
BP, WB, IHC
Catalog No. ABIN975605
Quick Overview for Diazepam Binding Inhibitor (DBI) (N-Term) Peptide (ABIN975605)
Target
Diazepam Binding Inhibitor (DBI)
Origin
Human
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
-
-
Protein Region
- N-Term
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-DBI antibody (Catalog #: ARP33135_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- Diazepam Binding Inhibitor (DBI)
-
Background
-
DBI is diazepam binding inhibitor. The protein that is regulated by hormones and is involved in lipid metabolism and the displacement of beta-carbolines and benzodiazepines, which modulate signal transduction at type A gamma-aminobutyric acid receptors located in brain synapses. DBI is conserved from yeast to mammals, with the most highly conserved domain consisting of seven contiguous residues that constitute the hydrophobic binding site for medium- and long-chain acyl-Coenzyme A esters. Diazepam binding inhibitor is also known to mediate the feedback regulation of pancreatic secretion and the postprandial release of cholecystokinin, in addition to its role as a mediator in corticotropin-dependent adrenal steroidogenesis. Three pseudogenes located on chromosomes 6, 8 and 16 have been identified. Multiple transcript variants encoding different isoforms have been described for this gene. This gene encodes diazepam binding inhibitor, a protein that is regulated by hormones and is involved in lipid metabolism and the displacement of beta-carbolines and benzodiazepines, which modulate signal transduction at type A gamma-aminobutyric acid receptors located in brain synapses. The protein is conserved from yeast to mammals, with the most highly conserved domain consisting of seven contiguous residues that constitute the hydrophobic binding site for medium- and long-chain acyl-Coenzyme A esters. Diazepam binding inhibitor is also known to mediate the feedback regulation of pancreatic secretion and the postprandial release of cholecystokinin, in addition to its role as a mediator in corticotropin-dependent adrenal steroidogenesis. Three pseudogenes located on chromosomes 6, 8 and 16 have been identified. Multiple transcript variants encoding different isoforms have been described for this gene.
Alias Symbols: ACBD1, ACBP, CCK-RP, EP, MGC70414
Protein Interaction Partner: PPCDC,TSPO
Protein Size: 87 -
Molecular Weight
- 10 kDa
-
Gene ID
- 1622
-
NCBI Accession
- NM_001079862, NP_001073331
-
UniProt
- P07108
Target
-
You are here:
